Omberacetam
Its synthesis was first reported in 1996.[ It is orally available. As of 2017, its metabolism and elimination half-life in humans were not well understood.][
]
It has been evaluated for neuroprotective effects in treating brain injuries and stroke.
Pharmacology
One oft-cited study (originally published in Russian) conducted on rats, suggests that Noopept works via the "antioxidant effect, the anti-inflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate, and to improve the blood rheology".
Some studies suggest that the pharmacological properties of Noopept are derived from its action as an activator of Hypoxia-inducible factor (HIF-1).
Dosage
Noopept is frequently dosed at 10–30 mg per day. However, there is no solid evidence indicating that any dose of Noopept is optimal. Few human trials have ever been carried out on Noopept, and as one meta-analysis notes, animal studies have used doses ranging from 0.1 mg/kg bodyweight to 10 mg/kg bodyweight.
Legal status
-
Hungary: As of 25 August 2020, Noopept is added to the controlled psychoactive substances list, prohibiting production, sale, import, storage and use.
-
Russia: Noopept in Russia is a drug of medicine and is available without a prescription.
-
United Kingdom: Contrary to popular belief, omberacetam is not illegal to produce, supply, or import under the Psychoactive Substance Act in the UK, which came into effect on May 26, 2016 because it neither works as a CNS (central nervous system) depressant, nor as a CNS stimulant.
-
United States: The Food and Drug Administration has issued import alerts for imports of omberacetam, considering it an analog of piracetam.
See also
Notes
